Loading
A Chinese cohort of up to 60,000 people built by Fudan University and Singlera to develop a blood test for many cancers.
FuSion (NCT05159544) is an observational study sponsored by Singlera Genomics Inc with Fudan University. It evaluates sensitivity, specificity and predictive values of a screening model developed by Fudan University and Singlera in a two-year follow-up cohort, and develops a multi-omic model in a community cohort.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 17 April 2024), with an estimated 60,000 participants, a start on 6 July 2021 and primary completion expected on 6 July 2024.
Shares Singlera Genomics, PanSeer, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Singlera Genomics, PanSeer, Multi-cancer early detection (MCED).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/